Alessandro Giollo
Alessandro Giollo currently serves as the lead of refractory arthritis, synovial biopsy and osteoporosis clinics at the Rheumatology Unit, University of Padova (Italy). His clinical work and research interests cover refractory and early RA, vasculitis, systemic sclerosis, and cardiovascular involvement of RMDs. Alessandro is a member of the Country Liaison Sub-Committee.
| Type, n° | Date, timE | Session | Author | Title |
|---|---|---|---|---|
| Poster 0632 | Thursday, 01.06.2023 09:30 –10:30 | Rheumatoid arthritis – biological DMARDs | Dijkshoorn, B (Netherlands) | TARGETING NET FORMATION IN EARLY RA PATIENTS; A SPIN-OFF STUDY FROM THE NORD-STAR |
| This study shows the relevance of NETs as a biomarker of clinical response to treatment for early RA. It used data from the NORD-STAR, an international, multicenter, open-label, assessor-blinded, phase 4 study. | ||||
| Poster 0864 | Thursday, 01.06.2023 14:45 – 15:45 | Rheumatoid arthritis – non biologic treatment and small molecules | Atienza-Mateo, B (Spain) | EFFECTIVENESS OF ANTIFIBROTICS IN RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE. NATIONAL MULTICENTER STUDY OF 50 PATIENTS IN CLINICAL PRACTICE |
| Clinical data on antifibrotics in RA-ILD are lacking. This study provides evidence for real-life effectiveness of antifibrotics in RA. | ||||
| Poster 0309 | Saturday, 03.06.2023 10:10 – 10:15 | Original perspectives on old DMARDs and new small molecules in rheumatoid arthritis | Crowson, L (USA) | TIME TRENDS IN GLUCOCORTICOID USE IN RHEUMATOID ARTHRITIS DURING THE BIOLOGICS ERA: 1999-2018 |
| This observational cohort shows that real world use of glucocorticoids in patients with RA is not optimal or improving despite advances in RA therapy. | ||||
| Oral 0220 | Friday, 02.06.2023 10:55 – 11:05 | Rheumatoid arthritis: new small molecules and old DMARDs | Van Ouwerkerk, L (Netherlands) | INITIAL GLUCOCORTICOID BRIDGING IN RHEUMATOID ARTHRITIS: DOES IT AFFECT GLUCOCORTICOID USE OVER TIME? |
| Merging data from seminal BeST, CareRA and COBRA trials, authors showed that GC bridgers had an increased risk of using GC at 12 months from baseline compared to non-bridgers, but not thereafter. | ||||
| Oral 0127 | Thursday, 01.06.2023 11:45 – 11:55 | Predictors of outcome in early rheumatoid arthritis | Venerito, V (Italy) | HARNESSING THE POWER OF RADIOMICS TO PREDICT SURVIVAL IN PATIENTS WITH RA-ILD |
| This study successfully exploited the role of radiomics to predict RA-ILD patients’ mortality. | ||||
| Oral 0219 | Friday, 02.06.2023 10:45 – 10:55 | Rheumatoid arthritis: new small molecules and old DMARDs | Aymon, R (Switzerland) | INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH JAK-INHIBITORS COMPARED TO BDMARDS: DATA FROM AN INTERNATIONAL COLLABORATION OF REGISTRIES (THE “JAK-POT” STUDY) |
| In this real-world study, including 14 RA registers and all currently available JAKi in the respective countries, there was not a significantly higher risk of MACE in RA patients treated with JAKi compared to TNFi. | ||||